{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"x_thread":4,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06645678\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MELT-MM","nct_id":"NCT06645678","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=melt-mm-nct06645678. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"MELT-MM","arms":[{"description":"Participants will receive elranatamab, mezigdomide and dexamethasone.\n\nPart 1 (safety cohort): approximately 12 participants to select the optimal RP2D and to assess the safety, tolerability, and preliminary efficacy. Every cycle consists of 28 days.\n\nPart 2 (expansion cohort): approximately 63 participants will be enrolled. The primary objective of Part 2 is to determine the overall response rate per IMWG criteria at 24 months after enrollment.","label":"Treatment arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"enrollment":{"count":75,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elranatamab","type":"DRUG"},{"name":"Mezigdomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2025-12-03","lead_sponsor":"YOUNGIL KOH","official_title":"Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate (ORR)","timeFrame":"From C1D1 to confirmed PD, lost to follow-up, or death (whichever occurs first), assessed up to 24 months"}],"references":[],"start_date":{"date":"2024-11-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06645678"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/melt-mm-nct06645678"}